{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:08:28Z","timestamp":1791875308990,"version":"4.3.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T00:00:00Z","timestamp":1536278400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1038\/s41433-018-0212-2","type":"journal-article","created":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T10:31:46Z","timestamp":1536316306000},"page":"295-303","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Clinical efficacy of eplerenone versus placebo for central serous chorioretinopathy: study protocol for the VICI randomised controlled trial"],"prefix":"10.1038","volume":"33","author":[{"given":"Abby","family":"Willcox","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Culliford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris A","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1987-8900","authenticated-orcid":false,"given":"Angela","family":"Cree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usha","family":"Chakravarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Ennis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francine","family":"Behar-Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5101-9487","authenticated-orcid":false,"given":"Barnaby C","family":"Reeves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8952-0659","authenticated-orcid":false,"given":"Sobha","family":"Sivaprasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5541-4305","authenticated-orcid":false,"given":"Andrew","family":"Lotery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,7]]},"reference":[{"key":"212_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/00006982-200202000-00004","volume":"22","author":"RH Loo","year":"2002","unstructured":"Loo RH, Scott IU, Flynn HW Jr, Gass JD, Murray TG, Lewis ML, et al. Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina. 2002;22:19\u201324. PubMed PMID: 11884873.","journal-title":"Retina"},{"key":"212_CR2","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1038\/eye.2010.130","volume":"24","author":"M Gemenetzi","year":"2010","unstructured":"Gemenetzi M, De Salvo G, Lotery AJ. Central serous chorioretinopathy: an update on pathogenesis and treatment. Eye (Lond). 2010;24:1743\u201356. \nhttps:\/\/doi.org\/10.1038\/eye.2010.130\n\n. PubMed PMID: 20930852.","journal-title":"Eye (Lond)"},{"key":"212_CR3","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1002\/humu.22551","volume":"35","author":"C Schubert","year":"2014","unstructured":"Schubert C, Pryds A, Zeng S, Xie Y, Freund KB, Spaide RF, et al. Cadherin 5 is regulated by corticosteroids and associated with central serous chorioretinopathy. Hum Mutat. 2014;35:859\u201367. \nhttps:\/\/doi.org\/10.1002\/humu.22551\n\n. PubMed PMID: 24665005; PubMed Central PMCID: PMCPMC4215937.","journal-title":"Hum Mutat"},{"key":"212_CR4","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1038\/eye.2014.134","volume":"28","author":"OC Erikitola","year":"2014","unstructured":"Erikitola OC, Crosby-Nwaobi R, Lotery AJ, Sivaprasad S. Photodynamic therapy for central serous chorioretinopathy. Eye (Lond). 2014;28:944\u201357. Epub 2014\/06\/21. \nhttps:\/\/doi.org\/10.1038\/eye.2014.134.\n\n PubMed PMID: 24946843; PubMed Central PMCID: PMCPMC4135258.","journal-title":"Eye (Lond)"},{"key":"212_CR5","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/j.ophtha.2008.04.014","volume":"115","author":"WM Chan","year":"2008","unstructured":"Chan WM, Lai TY, Lai RY, Liu DT, Lam DS. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology. 2008;115:1756\u201365. \nhttps:\/\/doi.org\/10.1016\/j.ophtha.2008.04.014\n\n. PubMed PMID: 18538401.","journal-title":"Ophthalmology"},{"key":"212_CR6","doi-asserted-by":"publisher","first-page":"CD011841","DOI":"10.1002\/14651858.CD011841.pub2","volume":"12","author":"M Salehi","year":"2015","unstructured":"Salehi M, Wenick AS, Law HA, Evans JR, Gehlbach P. Interventions for central serous chorioretinopathy: a network meta-analysis. Cochrane Database Syst Rev. 2015;12:CD011841. \nhttps:\/\/doi.org\/10.1002\/14651858.CD011841.pub2\n\n. PubMed PMID: 26691378.","journal-title":"Cochrane Database Syst Rev"},{"key":"212_CR7","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1038\/eye.2013.236","volume":"27","author":"YR Chung","year":"2013","unstructured":"Chung YR, Seo EJ, Lew HM, Lee KH. Lack of positive effect of intravitreal bevacizumab in central serous chorioretinopathy: meta-analysis and review. Eye (Lond). 2013;27:1339\u201346. Epub 2013\/11\/10. doi: 10.1038\/eye.2013.236. PubMed PMID: 24202051; PubMed Central PMCID: PMCPMC3869506.","journal-title":"Eye (Lond)"},{"key":"212_CR8","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1172\/Jci61427","volume":"122","author":"M Zhao","year":"2012","unstructured":"Zhao M, Celerier I, Bousquet E, Jeanny JC, Jonet L, Savoldelli M, et al. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest. 2012;122:2672\u20139. \nhttps:\/\/doi.org\/10.1172\/Jci61427\n\n. PubMed PMID: WOS:000306044600037.","journal-title":"J Clin Invest"},{"key":"212_CR9","first-page":"2096","volume":"33","author":"E Bousquet","year":"2013","unstructured":"Bousquet E, Beydoun T, Zhao M, Hassan L, Offret O, Behar-Cohen F. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study. Retina-J Ret Vit Dis. 2013;33:2096\u2013102. PubMed PMID: WOS:000330237900014.","journal-title":"Retina-J Ret Vit Dis"},{"issue":"7","key":"212_CR10","doi-asserted-by":"publisher","first-page":"e610","DOI":"10.1111\/aos.13491","volume":"95","author":"Roy Schwartz","year":"2017","unstructured":"Schwartz R, Habot-Wilner Z, Martinez MR, Nutman A, Goldenberg D, Cohen S, et al. Eplerenone for chronic central serous chorioretinopathy\u2014a randomized controlled prospective study. Acta Ophthalmol. 2017. Epub 2017\/06\/28. \nhttps:\/\/doi.org\/10.1111\/aos.13491.\n\n PubMed PMID: 28653813.","journal-title":"Acta Ophthalmologica"},{"key":"212_CR11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018.","volume":"116","author":"DM Brown","year":"2009","unstructured":"Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009;116:57\u201365e5. \nhttps:\/\/doi.org\/10.1016\/j.ophtha.2008.10.018.\n\n PubMed PMID: 19118696.","journal-title":"Ophthalmology"},{"key":"212_CR12","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419\u201331. \nhttps:\/\/doi.org\/10.1056\/NEJMoa054481\n\n. PubMed PMID: 17021318.","journal-title":"N Engl J Med"},{"key":"212_CR13","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1016\/j.ophtha.2007.06.047","volume":"114","author":"RW Beck","year":"2007","unstructured":"Beck RW, Maguire MG, Bressler NM, Glassman AR, Lindblad AS, Ferris FL. Visual acuity as an outcome measure in clinical trials of retinal diseases. Ophthalmology. 2007;114:1804\u20139. \nhttps:\/\/doi.org\/10.1016\/j.ophtha.2007.06.047\n\n. Epub 2007\/10\/03PubMed PMID: 17908590.","journal-title":"Ophthalmology"},{"key":"212_CR14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/0002-9394(82)90197-0","volume":"94","author":"FL Ferris III","year":"1982","unstructured":"Ferris FL III, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol. 1982;94:91\u20136. Epub 1982\/07\/01. PubMed PMID: 7091289.","journal-title":"Am J Ophthalmol"},{"key":"212_CR15","doi-asserted-by":"crossref","unstructured":"Hutton D, Smith N, Cappel-Porter H, Saw C, Rogers CA. Development of the \u201cGeneSYS\u201d database system to support trial data capture and conduct. 2013. In: Trials [Internet]. 29\/11\/2013. [66].","DOI":"10.1186\/1745-6215-14-S1-P66"},{"key":"212_CR16","unstructured":"NetWORC UK. Network of ophthalmic reading centres UK. Available from: \nhttp:\/\/www.networcuk.com\/\n\n."},{"key":"212_CR17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1475-1313.1993.tb00421.x","volume":"13","author":"BC Reeves","year":"1993","unstructured":"Reeves BC, Wood JM, Hill AR. Reliability of high- and low-contrast letter charts. Ophthalmic Physiol Opt. 1993;13:17\u201326. Epub 1993\/01\/01. PubMed PMID: 8510943.","journal-title":"Ophthalmic Physiol Opt"},{"key":"212_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/09273970601172435","volume":"15","author":"R Becker","year":"2007","unstructured":"Becker R, Teichler G, Graf M. Reproducibility of visual acuity assessment in normal and low visual acuity. Strabismus. 2007;15:3\u20136. \nhttps:\/\/doi.org\/10.1080\/09273970601172435\n\n. Epub 2007\/05\/25PubMed PMID: 17523039.","journal-title":"Strabismus"},{"key":"212_CR19","unstructured":"Clinical efficacy and mechanistic evaluation of Eplerenone for central serous chorio-retinopathy the VICI study. 2016. Available from: \nhttps:\/\/njl-admin.nihr.ac.uk\/document\/download\/2009989\n\n."}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41433-018-0212-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41433-018-0212-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41433-018-0212-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:05:17Z","timestamp":1684616717000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-018-0212-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,7]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["212"],"URL":"https:\/\/doi.org\/10.1038\/s41433-018-0212-2","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,7]]},"assertion":[{"value":"6 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AW, LC, LE, CAR, AC, SE and BCR have no conflicts of interest. FB-C is an inventor on a patent protecting the use of MR antagonists in CSCR. SS has received research grants, travel grants, and speaker fees from Novartis, Bayer, Allergan, Roche, Heidelberg Engineering, and Optos. AL has received travel grants and speaker fees from Bayer and Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The views expressed in this publication are those of the author(s) and not necessarily those of the MRC, NHS, NIHR or the Department of Health.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}